{
    "symbol": "TGTX",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-08 14:24:03",
    "content": " I am pleased to provide an update on our core commercial activities as we continue to accelerate our preparation for the anticipated ublituximab launch in relapsing forms of MS. Our objectives through the launch of ublituximab are to: one, build a team of experienced professionals with deep knowledge of the MS landscape and strong relationships across the MS community; two, ensure we are in a position to facilitate seamless access to ublituximab for patients and providers and three, drive demand for ublituximab at approval with MS specialists based on its differentiated profile."
}